Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
Portfolio Pulse from
Cardiff Oncology has announced positive initial data from its Phase 2 CRDF-004 trial for first-line RAS-mutated metastatic colorectal cancer (mCRC). The trial showed a 64% overall response rate (ORR) in the 30mg onvansertib dose arm compared to 33% in the control arm.
December 10, 2024 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cardiff Oncology's Phase 2 trial for RAS-mutated mCRC shows promising results, with a 64% ORR in the 30mg onvansertib dose arm, potentially boosting investor confidence.
The positive initial data from the Phase 2 trial indicates a significant improvement in ORR for the 30mg onvansertib dose arm compared to the control. This could lead to increased investor confidence and a potential rise in stock price due to the promising efficacy of the treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100